Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer

Posted on 22 September 2020

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer is an article from Biochim Biophys Acta Rev Cancer.

"The idea of using known and approved drugs for new indications has recently gained considerable momentum in many fields of medicine, especially in complex disorders. This approach presents an important advantage, as compared to the "de novo" drug discovery process, by considerably reducing the cost and time to bring a new treatment to patients. Drug repurposing, a term also referred to as repositioning or redirection, might be compared to giving a new use to an existing tool that already comes with a technical handbook: repurposed drugs have well-documented toxicity, pharmacology and drug-drug interaction parameters. Moreover, rescuing drugs that failed in one indication can deliver a potential drug candidate to another. The current status of drug repurposing is collected in the reproDB site (http://apps.chiragjpgroup.org/repoDB/). It is encouraging that the EMA in Europe, as well as the NIH and the FDA in the USA have already launched drug repurposing programs to identify new uses for existing pipeline medications developed by the pharmaceutical industry."

Click here to read or download the PDF.

Author: Vitawell
Tags: Resources Most Popular

Associations

  • The Institute for Functional Medicine
  • Society for Integrative Oncology
  • American Society of Clinical Oncology
  • Australasian Integrative Medicine Association
  • Naturopaths and Herbalists Association of Australia
  • British Naturopathic Association

Disclaimer: Manuela Boyle is not a registered medical practitioner or specialist medical oncologist. Manuela Boyle is a general health service provider who is not legally required to be registered under National Health Practitioner regulation law. She practises under the national Code of Conduct that sets standards to general health service providers who are not regulated by the Australian Health Practitioner Regulation Agency.

Manuela Boyle is an accredited member of the following professional organisations:
NHAA (Naturopaths & Herbalists Association of Australia), SIO (Society of Integrative Oncology) USA, AIMA (Australasian Integrative Medical Association), IFM (Institute of Functional Medicine) USA